Table 3. miR-183-96-182 cluster for prediction of cancer prognosis.
| Member of miR-183-96-182 cluster | Oncogene/Tumor suppressor | Cancer types | Target genes | Results |
|---|---|---|---|---|
| miR-183-96-182 | Oncogene | Hepatocellular carcinoma (tissue) | FOXO1 | Associated with prognosis (microvascular invasion, tumor differentiation, and patients survival) [13]. |
| miR-183-96-182 | Oncogene | Lung cancer (tissue and serum) | -- | Associated with prognosis (survival) [48]. |
| miR-183, miR-96 | Oncogene | Prostate cancer (tissue) | -- | Associated with prognosis (tumor aggressiveness, metastatic and overall survival) when combined with other microRNAs [131]. |
| miR-183 | Oncogene | Lung cancer (tissue)* | -- | Associated with prognosis (lymph node metastasis, clinical stage and EGFR mutation and patients survival) [179]. |
| miR-183 | Oncogene | Breast cancer (tissue) | -- | Associated with prognosis (TNM clinical stage) [129]. |
| miR-183 | Oncogene | Colorectal cancer (plasma) | -- | Associated with cancer recurrence and prognosis (lymph node metastasis, distant metastasis, TNM stage) [132]. |
| miR-183 | Oncogene | Colorectal cancer (tissue) | -- | Associated with prognosis (clinical stage, lymph node metastasis, distant metastasis and patients survival) [133]. |
| miR-183 | Oncogene | Hepatocellular carcinoma (tissue) | -- | Associated with cancer progression (TNM stage and cirrhosis), but not with patient survival [130]. |
| miR-183 | Oncogene | Hepatocellular carcinoma (serum) | -- | Associated with prognosis (TNM stage and postoperative survival) [180]. |
| miR-183 | Tumor suppressor | Lung cancer (serum) * | -- | Associated with prognosis (metastasis) [137]. |
| miR-183 | Tumor suppressor | Osteosarcoma (tissue) | EZR | Associated with aggressiveness and poor prognosis (tumor grade, response to chemotherapy, metastasis and recurrence) [135]. |
| miR-183 | - | Prostate cancer (cancer cell) | KLK3/PSA | miR-183 binds to the 3′ UTR of PSA and increases its protein and mRNA levels [136]. |
| miR-96 | Oncogene | Prostate cancer (tissue) | -- | Associated with prognosis (tumor stage, recurrence and survival) [138]. |
| miR-96 | Oncogene | Prostate cancer (tissue) | -- | Not correlates with prognosis (biochemical recurrence and clinicopathological parameters) [139]. |
| miR-96 | Oncogene | Hepatocellular carcinoma (tissue) | LRP6, FOXO1A, and MAP2K1 (Not biologically validated) | Associated with prognosis (recurrence) when combined with other microRNAs [140]. |
| miR-96 | Oncogene | Colorectal cancer (tissue) ** | -- | Associated with prognosis (overall survival)[32] |
| miR-96 | Tumor suppressor | Colorectal cancer (plasma) ** | KRAS | Associated with prognosis (distant metastasis and survival) [181]. |
| miR-96 | Acute myeloid leukemia (mononuclear cells) | -- | Associated with prognosis (relapse-free survival and overall survival) [141]. | |
| miR-182 | Oncogene | Nasopharyngeal carcinoma (tissue) | -- | Associated with prognosis (overall survival, disease-free survival, and distant metastasis) [144]. |
| miR-182 | Oncogene | Pancreatic cancer (plasma) | -- | Associated with prognosis (Clinical stages, lymph node metastasis and survival) [143]. |
| miR-182 | Oncogene | Breast cancer (tissue) | -- | Associated with prognosis (lymph node metastases and grade III occurrence) [142]. |
| miR-182 | Oncogene | Colon cancer (tissue) | FBXW7 | Associated with prognosis (Survival) [145]. |
| miR-182 | Oncogene | Colorectal cancer (tissue) | -- | Associated with prognosis (T-stage, lymph node metastasis, distant metastasis, Dukes' stage, and survival) [146]. |
| miR-182 | Oncogene | Colorectal cancer (tissue) | -- | Associated with prognosis (TNM stage, lymph node metastasis, and survival) [147, 148]. |
| miR-182 | Oncogene | Prostate cancer (tissue) | -- | Associated with prognosis (T stages, Gleason score, TMPRSS2-ERG status, and patient survival) [149]. |
| miR-182 | Oncogene | Bladder cancer (tissue) | -- | Associated with prognosis (aggressiveness and survival) [150]. |
| miR-182 | Oncogene | Glioma (tissue) | -- | Associated with prognosis (overall survival) [151]. |
| miR-182 | Tumor suppressor | Lung cancer (tissue) | -- | Associated with prognosis (disease-specific survival) [152]. |
*
Contradictory findings were marked as the same number of *.
Abbreviations: EZR: Ezrin; FBXW7: F-box and WD repeat domain containing 7, E3 ubiquitin protein ligase; FOXO1A: Forkhead box O1a; KLK3/PSA: Kallikrein-related peptidase 3; KRAS: Kirsten rat sarcoma viral oncogene homolog; LRP6: Low density lipoprotein receptor-related protein 6; MAP2K1: Mitogen-activated protein kinase kinase 1